Kidney Safety in Clinical Trials and Real-World Studies The SUSTAIN-6 trial, which followed over 3,000 patients with type 2 diabetes for nearly two years, documented that semaglutide significantly reduced the risk of new or worsening kidney disease compared to placebo
Blood levels are accumulating
carried out two 12-week studies offering different results: the first study showed that liraglutide was superior to metformin in reducing body weight, BMI, and WC [57], while in the second study, both the treatments proved to be equally effective with no differences between the groups [58]
Drugs and Lactation Database (LactMed) - National Library of Medicine ZEPBOUND (tirzepatide) injection, for subcutaneous use FDA Tirzepatide - StatPearls Metformin - Drugs and Lactation Database (LactMed) How May GIP Enhance the Therapeutic Efficacy of GLP-1
Rosen R, Hu DN, Perez V, et al
BBR can obviously promote the above metabolic processes, so it can ameliorate the organ function damage caused by metabolic related diseases to a certain extent
